TGF-β RI Kinase Inhibitor III is a cell-permeable imidazolyl-pyridine compound that acts as a potent, ATP-competitive, reversible, and selective inhibitor of ACTR-IB (activin receptor-like kinase 4, IC50 = 129 nM), TGF β RI (activin receptor-like kinase 5, IC50 = 47 nM), and ACTR-IC (activin receptor-like kinase 7). TGF-β RI Kinase Inhibitor III inhibits p38 MAPKα only at much higher concentrations IC50 = 10.6 βM) and has little effect against ALK1/2/3/6 as well as a panel of 26 other kinases.
Hu, T., et al. 2005. Am. J. Physiol. Renal Physiol. 289, F816. DaCosta Byfield, S., et al. 2004. Mol. Pharmacol. 65, 744.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.